Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-P17 pediatric newly diagnosed APL chemotherapy-reduction study
jRCTs031230727Phase 2Recruiting
- Sponsor
- Tokyo Metropolitan Hospital Organization
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tretinoin, arsenic trioxide and idarubicin in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Tokyo Metropolitan Hospital Organization. Primary endpoint: Two-year event-free survival. Started Mar 2024; status: recruiting.
02
Drugs
tretinoinarsenic trioxideidarubicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs031230727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230727.